Herskowitz Neil 4

What Happened
Neil Herskowitz, a director of Journey Medical Corp (DERM), was granted 10,000 restricted stock units (RSUs) on June 25, 2026. The award was reported as an acquisition on a Form 4 filed June 26, 2026. The RSUs were granted at a $0.00 purchase price (i.e., an equity award rather than a cash purchase).

Key Details

• Transaction date: June 25, 2026; Form 4 filed June 26, 2026 (timely filing).
• Grant: 10,000 RSUs, reported at $0.00.
• Vesting: Footnote F1 states the 10,000 RSUs vest in full on June 25, 2027.
• Footnote F2 notes the filing includes RSUs that vest over various time periods (likely describing other holdings or awards).
• Shares owned after transaction: not specified in the filing.
• Transaction type: A = Award/Grant (not a market purchase or sale).

Context
Restricted stock units are equity awards that convert into actual shares only upon vesting and typically are subject to forfeiture until then. This grant is a compensation award to a director and does not represent an open‑market buy or sell; such awards are common and should be interpreted as compensation rather than a direct buy/sell signal.